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1. Introduction 
Circulating prostaglandins (PG) of the E and F 
series are rapidly inactivated, mainly in the lung [ 11, 
by the enzymes 1 S-hydroxy-PGdehydrogenase nd 
PG-A13-reductase [2]. Thus, levels of the 15keto- 
13,14dihydro metabolites in plasma reflect more 
accurately PG biosynthesis than levels of the primary 
PG [2]. On the other hand, prostacyclin (PG12) has 
been suggested to be a circulating hormone [3,4], as 
its biological activity is not significantly diminished 
during passage through the lung [5], probably because 
it is not a substrate for the PG transport system across 
the cell membranes [6]. In aqueous olution PGIZ is 
hydrated to the biologically much less active 6-keto- 
PGFro [7], which is only slowly metabolized by 
15-hydroxy-PGdehydrogenase ndPG-A13-reductase 
[8,9]. Contrary to 6-keto-PGFro, PGIZ has a high 
affinity for 15-hydroxy-PGdehydrogenase of several 
organs [9-l l] including vascular tissue [12] in vitro. 
While in the rat in vivo in one study [13] no metabo- 
lism of 6-keto-PGFio via the 15-hydroxy-PGdehydro- 
genase pathway was observed, in other studies using 
different experimental conditions considerable oxida- 
tion of the C-l 5 hydroxyl group and reduction of the 
Al3 double bond of exogenous PGI? [6,14] and to a 
smaller extent of 6-keto-PGFro [ 141 have been shown 
to occur. The stable metabolites of PGIz resulting 
from these enzyme reactions followed by hydration 
are 6,15diketoPGFro and 6.15-diketo-13,14-dihy- 
dro-PGF,,. We describe here radioimmunoassays for 
these two PGIZ metabolites and determinations of
the occurrence of these compounds in rat vascular 
tissue incubated in vitro as well as in rat and human 
plasma. 
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2. Materials and methods 
PG and PG metabolites were a generous gift of 
Dr J. Pike, The Upjohn Co., Kalamazoo, MI. The 
haptens 6,15-diketo-PGFro’and 6,15diketo-13,14- 
dihydro-PGFro were made immunogenic by coupling 
to bovine serum albumin (BSA, A grade, Calbiochem, 
San Diego, CA) by the method in [ 151. BSA (7.5 mg) 
was dissolved in 2.5 ml distilled water and 4 mg 
1 ethyl-3(3dimethylaminopropyl)carbodiimide 
hydrochloride (Ott Chemical Co., Muskegon, MI) was 
added. Then 3 mg hapten, dissolved in 0.2 ml dimeth- 
ylformamide plus 1.7 ml 0.9% NaCl was added drop- 
wise, the solution was stirred at room temperature for 
1 h, then incubated overnight. The conjugate was 
dialyzed exhaustively against distilled water. 
Rabbits were immunized by the schedule in [ 161 
and blood was taken by puncture of the ear artery 
lo-14 days after booster injections. The blood was 
collected into 7.5% (v/v) of 77 mM sodium EDTA 
plus 0.1 mM indomethacin (final cont.) to inhibit 
synthesis of PG and thromboxanes (TX) by blood 
cells. The antiplasma was immediately separated from 
the blood cells by centrifugation at 4’C (1000 X g, 
15 min). 
The labelled ligands for both PGIz metabolite 
radioimmunoassays were prepared by incubation of 
5 /.&i [9-3H(N)]PGIz (spec. act. 10.0 Ci/mmol, New 
England Nuclear Co., Dreieichenhain) as substrate 
with 1 .O ml 100 000 X g supernatant of guinea pig 
lung homogenate as enzyme source and 1 mM NAD 
as coenzyme in 1 .l ml total vol. The lung of one 
guinea pig was homogenized in 30 ml 0.1 M ice-cold 
potassium phosphate buffer (pH 7.4) containing 1 pg/ 
ml indomethacin i order to prevent synthesis of PG 
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and TX during the enzyme preparation procedure. 
Incubations were performed at 37*C for 4 min for 
the synthesis of the tritiated ligand for the radio- 
immunoa~ay of 6,15-diketo-PGF~* and for 60 mm 
for the synthesis of the tritiated ligand for the radio- 
immunoassay of 6,15-diketo-13,14-dihydro-PGF,, 
After acidification to pH 3.5 the incubation mixtures 
were extracted twice with 10 ml ethyl acetate. The 
combined extracts were evaporated and purified by 
thin-layer chromatography (solvent system: ethyl 
acetate/H201isooctane/acetic acid, 110: 100:50:20, 
by vol., upper phase, developed twice). The zones 
containing the radioactivity co-chromatographing 
with the authentic standards were eluted with meth- 
anol and used as tracers in the radioimmunoassays, 
An antiplasma against 6,15_diketo-PGFro bound 50% 
of the homologous tracer at a final dilution of 1:2000, 
whileanantiplasmaagainst 6,15_diketo-13,14dihydro- 
PGFro bound 50% of its homologous tracer at a final 
dilution of 1:60 000. 
Radioimmunoassays were performed as in [ 161 for 
the determination of other PG, using either charcoal 
suspension or, in the case of plasma, the double anti- 
body method with goat anti-rabbit y-globulin (Cal- 
biochem, San Diego, CA) as precipitating antibody to 
separate free and antibody-bound fractions of antigen. 
Charco~-adsorbed plasma [16] was used as a PG-free 
reference plasma pool. 
Rat thoracic and abdominal aorta (100 mg wet wt) 
was taken from ether-anesthetized animals (200- 
300 g). The tissue was cut into small pieces, washed 
and incubated in 2.0 ml Krebs-Henseleit bicarbonate 
buffer (pH 7.4) gassed with 95% Os-5% COs, at 37°C 
for various time intervals. Aliquots of the incubates 
were analyzed in the radioimmunoassays for 6-keto- 
PGFro as well as for the PGIz metabolites. To further 
characterize the imm~oreactive PGIz metabolites 
minced aortic tissue (200 mgj was incubated in 0.2 ml 
Krebs-Henseleit bicarbonate buffer and a 0.1 ml ali- 
quot of the incubate was spotted onto a thin-layer 
plate (Kieselgel60, Merck, Darmstadt) and chromatog- 
raphed twice along with authentic standards using the 
above solvent system. After development the zones 
corresponding to the PGIs metabolites were eluted 
with methanol and rechromatographed. Then the area 
of the plate, where the material from the incubate 
had been developed, was cut into 1 cm zones from 
origin to solvent front. The zones were eluted with 
1 .O ml methanol. The methanol was evaporated and 
the residues were analyzed in the radioimmunoa~ays 
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for 6,15-diketo-PGFroand 6,15diketo-13,14- 
dihydro-PGFro. 
Blood from healthy volunteers (age 19-30 years, 
3 male, 5 female) was drawn by venipun~ture from 
the antecubital vein. Blood from ether-~esthetized 
rats was taken from the carotid artery. The blood 
samples were collected into a mixture of sodium EDTA 
and indomethacin as described for the antiplasma 
obtained from immunized rabbits. The plasma was 
immediately separated from blood cells by centrifuga- 
tion and the samples were stored frozen (-2O’C) until 
assayed. 
3. Remits and discussion 
The specificity of the antibodies against 6,15- 
diketo-PGFro and 6,15-diketo-13,14dihydro-PGFro 
is shown in table 1. Both radioimmunoassays recognize 
the 15keto group as an immunodominant part of the 
hapten molecules. In addition, the presence or absence 
of the Al3 double bond in the PGIz metabolite mole- 
cules can be determined by the simultaneous se of 
both radioimmunoassays. The relative cross-reaction 
of related PG metabolites also shows that compounds 
with the immunodom~~t 15-keto group have a high 
affinity for the antibodies. However, the si~i~c~t 
cross-reaction by 1 S-keto-PGEz and 15-keto-PGFso 
does not invalidate the radioimmunoassays, a  these 
compounds are usually rapidly converted to the corre- 
sponding 15.keto-13,14-dihydro metabolites [2]. 
Table 2 shows, that a whole cell preparation of rat 
aorta releases in a time-dependent manner not only 
large amounts of immunoreactive 6-keto-PGFro, the 
hydration product of PGI1, but also significant quan- 
tities of immunoreactive PGIs metabolites. The PGIz 
metabolites formed during the incubation were addi- 
tionally characterized by thin-layer chromatography. 
These experiments demonstrated that the immuno- 
reactive PGIs metabolites co-chromatograph exclu- 
sively with the corresponding authentic standards. An 
example is shown in fig.1. These results validate the 
data obtained by direct radioimmunoassay of the 
incubates and exclude the possibility, that cross- 
reacting 6-keto-PGFro accounts for the immunoreac- 
tivity determined in the radioimmunoassays for 6,15- 
diketo-PGFro and 6,15diketo-13,14-dihydro-PGFro. 
Although 6,15-diketo-PGFro and 6,15-diketo- 
13,14d~ydro-P~F~~ can be formed from 6-keto- 
PGFro [8,9], PGIs has a much higher affinity for the 
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Table 1 
Specificity of the radioimm~o~~ys for 6,lSdiketoPGF,, and 6,15diketo-13,14- 
diydro-PGF,, 
Inhibitor 
(ng) 
6,1SdiketoPGF,, 
6,15diketo-13,14- 
dihydro-PGF,, 
Wketo-PGE, 
lZ&eto-PGF,, 
Wreto-13,14- 
dihydro-PGF,& 
15-keto-13,14- 
dihydro-PGE, 
6-keto-PGF,, 
PGE* 
PGF*e 
PGD, 
-PXB, 
50% displacement of labelled l&and in radioimmunoassay for: 
ti,lSdiieto- Relative cross- 6,l S-dfketo-13,14- Relative cross- 
PGF,, reaction (%) dihydro-PGF,, reaction (%) 
0.30 100 3.90 5.6 
1.32 22.7 0.22 100.0 
2.17 13.8 7.50 2.9 
2.87 10.5 35.00 0.6 
14.50 2.1 2.60 8.5 
16.50 1.8 17.50 1.3 
21.50 1.4 46.00 0.5 
260.00 0.1 >500.00 <0.04 
>500.00 <0.06 >500.00 CO.04 
>500.00 <0.06 >500.00 <0.04 
>500.00 <0.06 >500.00 <0.04 
-~ 
t l 
z I 
B 
B 
1 S-hydroxy-~-dehydrogen~e then has 6-keto-PGFSQI 
[9-l 21. We therefore assume that the metabolites are 
formed from PGIz rather than from 6-keto-PGFlcr. 
Using the cytoplasmic fraction of bovine mesenteric 
vessels as enzyme source and exogenous tritiated PGIz 
or 6-keto-PGFla, as substrate [ 121 it was found that 
Fig.1. Thin-layer chromatographic haracterization (solvent 
system: ethyl acetate/H,O/isooctane/acetic a id, 11O:lOO: 
50:20, by vol., upper phase) of immunorea~ve 6,15diketo- 
13,14dihydro-~F,~ released from a whole cell preparation 
of rat aorta. The imm~orea~ive material co~hromato~aphs 
as a single peak with the authentic standard. Spot (1) 6-keto- 
PGF,,, (2) 6,lSdiietoPGF,,, (3) 6,15diketo-13,14- 
dihydro-PGF,,. 
Table 2 
Timedependent releaie of immrmoreactive 6-keto-PGF,o, 6,15diketoPGF,, 
and 6,15diketo-13,14dihydroPGF,o from a whole cell preparation of rat aorta 
incubation 
time (mm) 
(i-keto-PGF,, 6,l Sdiketo- 
PGF,, 
6,15diketo-13,14- 
dihydro-PGF~~ 
3 644 f 157 51+7 25 + 3 
10 2607 * 492 134+7 79 c 9 
Values are given in pg/mg wet wt and are the mean f SEM of 6 expt 
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only [3H]PGIz was metabolized extensively, while 
most of the 6-keto-[3H]PGFla was recovered 
unchanged. Under the conditions used by these authors 
with exogenous substrate, added NAD or NADP as 
cofactors and a short incubation time (max. 2 min) 
the reaction product formed from PGI? was identified 
as 6,15-diketo-PGFro. We find with a whole cell prep- 
aration of rat aorta as enzyme source, endogenous 
substrate and endogenous enzyme cofactors and 
longer incubation periods pecific inhibition of the 
antigen-antibody reaction in both the radioimmuno- 
assay for 6,15-diketo-PGFro and 6,15-diketo-13,14- 
dihydro-PGFro’(table 2). Obviously a mixture of 
both PGIz metabolites i formed under our experi- 
mental conditions. The conditions used in [ 121 might 
have delayed the expression of PC A13-reductase 
activity [17]. 
The levels of the PGIz mctabolites in unextracted 
normal rat (n = 10) and human (n = 8) plasma were 
found to be below the detection limits of the radio- 
immunoassays for 6,15-diketo-PGFio and 6,15- 
diketo-13,14-dihydro-PGFio (25 pg/ml and 45 pg/ml, 
respectively). However, various amounts of exogenous 
PGIa metabolites (50 pg/ml-10 ng/ml) added to rat 
or human plasma were recovered quantitatively 
indicating that the failure to detect measurable 
amounts of these compounds in normal plasma is not 
due to non-specific factors interfering with the assay 
method, e.g., binding to plasma proteins. Our results 
suggest that the low or even undetectable vels of 
PGIa and 6-keto-PGFio [18-201 found in peripheral 
plasma under normal unstimulated conditions are 
obviously not caused by extensive metabolism to the 
6,15-diketo and 6,15diketo-13,14-dihydro deriva- 
tives. The possible formation of these PGIz metabo- 
lites in vivo during adminstration of exogenous PC+ 
or under conditions of stimulated endogenous PGIZ 
synthesis i  presently under investigation. 
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